Janux Therapeutics, Inc.
JANX
$16.12
$0.120.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 35.11% | -3.63% | -58.02% | 13.35% | -468.18% |
| Total Depreciation and Amortization | -14.42% | -9.63% | -8.59% | -1.76% | 6.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.33% | 2.53% | 80.23% | -64.60% | 106.68% |
| Change in Net Operating Assets | 641.79% | 1,051.55% | -785.51% | -49.06% | 151.01% |
| Cash from Operations | 152.43% | 27.53% | -70.65% | -476.24% | -137.63% |
| Capital Expenditure | 57.29% | 26.42% | -152.38% | -272.00% | -397.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,995.92% | 102.52% | -12.71% | -33.86% | 101.07% |
| Cash from Investing | -2,582.97% | 102.43% | -12.92% | -34.46% | 100.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 134.80% | 293.45% | -99.24% | -70.10% | -65.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 134.80% | 539.89% | -99.24% | -70.10% | -65.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.97% | 99.86% | -99.02% | -133.55% | 89.25% |